

Astellas Pharma US, Inc

[View the current Astellas Pharma US, Inc Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/23192-Astellas+Pharma+US%2CInc.html)

(<http://www.bioportfolio.com/biocorporate/23192-Astellas+Pharma+US%2CInc.html>)

Contact Details:

**3 Parkway North
Deerfield
Illinois
60015
United States of America**

Tel: 800.695.4321

Fax:

Email:

Astellasreimbursement@quorumconsulting.com

Launched in April 2005, Astellas was formed by the historical merger of Japan's third and fifth largest pharmaceutical companies - Yamanouchi, founded in 1923, and Fujisawa, founded in 1894. Both companies possessed similarities where it matters most- philosophy and vision. But the companies also differed where it matters most - areas of therapeutic concentration and expertise.

Yamanouchi brought a record of developing blockbuster drugs, a pipeline full of promising new compounds like Fujisawa, a sales and marketing culture of deeply grounded, data-driven expertise.

Fujisawa brought dominance in transplantation, a soaring reputation for in-depth understanding of the disease states and treatments within its market niches, and a track record for developing high-profile, market-leading products that become new standards of care.

With an unrelenting commitment to R&D as a value-creating core of its business, Astellas is consolidated around complementary strengths from Yamanouchi and Fujisawa. Astellas stands on a much stronger, more advanced business platform than either of the former companies could have mounted individually.

Press Releases on Astellas Pharma US, Inc:

Cytochroma to Present at 21st Annual Piper Jaffray Health Care Conference	25th November, 2009	Cytochroma	<i>MARKHAM, ON, Nov. 25 /PRNewswire/ - Cytochroma today announced that Charles W. Bishop, PhD, President and CEO, will be presenting a corporate overview at the 21st Annual Piper Jaffray Health Care</i>
Cytochroma Announces Appointment of Peter Moldt to Board of Directors	25th November, 2009	Cytochroma	<i>MARKHAM, ON, Nov. 25 /PRNewswire/ - Cytochroma today announced the appointment of Peter Moldt, PhD to its Board of Directors. Dr. Moldt will replace Mr. Ulrik Spork as the Novo A/S representative on</i>

Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis	25th November, 2009	Reportlinker	NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Intranasal Drug Delivery - US Market Trends & Analysis http://www
Reportlinker Adds Regenerative Medicine - Global Market Trends	25th November, 2009	Reportlinker	NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Regenerative Medicine - Global Market Trends http://www.reportlinker.com
Reportlinker Adds Pain Management - Global Trends	25th November, 2009	Reportlinker	NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Pain Management - Global Trends http://www.reportlinker.com/p0164220/Pain

BioNews Results for Astellas Pharma US, Inc



- [Astellas Pharma signs logistics management pact with Vardhman Health for Prograf](#)
PharmaBiz: Nov 18 2009 2:36PM Matching: astellas pharma us inc
- [Medical News: NeurogesX To Hold Conference Call To Discuss FDA Approval Of Qutenza\(TM\) \(capsaicin\) 8% Patch For Treatment Of Postherpetic Neuralgia \(PHN\)](#)
BioFind: Nov 18 2009 3:02PM Matching: astellas pharma us inc
- [Maxygen Buying Back Stock; Analysts Say No Trend Here](#)
BioWorld: Nov 14 2009 6:06AM Matching: astellas pharma us inc
- [Bioniche Pharma Acquires Duraclon\(R\) \(clonidine hydrochloride injection\) and Methadone Hydrochloride Injection](#)
Business Journal of Jacksonville: Nov 13 2009 1:40AM Matching: astellas pharma us inc
- [Bioniche Pharma Acquires Duraclon\(R\) \(clonidine hydrochloride injection\) and Methadone Hydrochloride Injection](#)
Pittsburgh Business Times: Nov 13 2009 12:03AM Matching: astellas pharma us inc
- [Astellas Pharma Inc. \(JOBS\) Buys Rights to New IBS Drug from Ironwood: Astellas Will Pay \\$75 Million Upfront](#)
BioSpace: Nov 11 2009 1:57AM Matching: astellas pharma us inc
- [Astellas Pharma Europe Announces Save the Children as a Winner of the Changing Tomorrow 2009 Awards](#)
PharmiWeb: Nov 11 2009 4:30AM Matching: astellas pharma us inc
- [Ironwood Licenses Bowel Drug Linaclotide to Astellas for \\$75M](#)
Therapeutics Daily: Nov 11 2009 2:51AM Matching: astellas pharma us inc
- [Astellas Pharma Boosted By Rights To Sell Constipation Drug In Asia](#)
Nikkei Net Interactive: Nov 11 2009 3:46PM Matching: astellas pharma us inc
- [Theravance, Astellas Pharma launch Vibativ in US to treat complicated skin & skin structure infections](#)
PharmaBiz: Nov 10 2009 9:03AM Matching: astellas pharma us inc
- [Ironwood and Astellas Announce Japan Licensing Agreement for Linaclotide](#)
Pharma Live: Nov 10 2009 5:05PM Matching: astellas pharma us inc
- [Ironwood and Astellas Announce Japan Licensing Agreement for Linaclotide](#)

Therapeutics Daily: Nov 10 2009 11:21AM Matching: astellas pharma us inc

- [Astellas Pharma Europe Announces Save the Children as a Winner of the Changing Tomorrow 2009 Awards](#)

Therapeutics Daily: Nov 10 2009 11:20AM Matching: astellas pharma us inc

- [Astellas Pharma Europe Announces Save the Children as a Winner of the Changing Tomorrow 2009 Awards](#)

EuroInvestor.co.uk: Nov 10 2009 6:32AM Matching: astellas pharma us inc

- [Ironwood Pharmaceuticals Inc signs licensing agreement with Astellas Pharma Inc for linaclotide](#)

TradingMarkets: Nov 10 2009 1:24PM Matching: astellas pharma us inc

Astellas Pharma US,Inc Clinical Trials:



- [A Study of the Safety and Efficacy of Tacrolimus Inhalation Aerosol in Subjects With Persistent Asthma](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

